| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
The disease mechanisms underlying psychiatric disorders remain largely undetermined. Schizophrenia is a mental illness featuring three major symptomatic domains: positive symptoms, negative symptoms and cognitive deficits. It presents with a prevalence of approximately 1% worldwide, making it a relatively common disease. Increasing clinical evidence indicates that sphingolipids are implicated in the pathogenesis of schizophrenia.
To figure out the involvement of sphingolipids in schizophrenia, I analyzed sphingolipids of postmortem brains from schizophrenia patients. Our mass spectrometry-based lipidomic approach demonstrated a change of sphingolipids in the corpus callosum of schizophrenia patients. Furthermore, the gene expression level of sphingolipid-metabolic enzymes and sphingolipid receptors altered in schizophrenia. From these findings, it is thought that dysregulation of sphingolipid receptor functions causes in the brain of schizophrenia patients.
|
